BOT - Anything but charting, page-5138

Once 15 cents goes there is not much left to prevent it from running to 20 cents in quick time.

And with good reason, by way of reminder (pretty sure euroz mentioned this some time ago):

The comparative market caps from NDA filing all the way through to FDA Approval to companies that most compare to botanix:


CUV - Clinuvel @ NDA Filing $593 mill market cap and @ FDA Approval $2.2 bill market cap. (Currently $876 million).

TLX - Telix Pharma @ NDA Filing $491 mill market cap and @ FDA Approval $2.4 bill market cap. (Currently $3.7 billion)

NEU - Neuren Pharma @NDA Filing $521 mill market cap and @ FDA Approval $1.1 bill (Currently $1.7 billion)

Botanix currently sits at around $184 million.

There is so much upside here given Botanix has products in already advanced phase 2 (BTX 1801) and phase 3 markets (BTX 1503) beyond the market for Sofpironium Bromide which is near FDA approval.

FDA approval could happen imminently.

There is some really good research available on the Botanix website. I suggest anyone new here read the following from Euroz to become familiar with the potential:

BOT.ASX-BOT-Successful-FDA-MidCycle-Review-040623.pdf (botanixpharma.com)